First Quarter Fiscal 2024 Financial Summary(All comparisons are year-over-year unless otherwise noted) Revenues of $16.7 million compared to $37.1 million […]
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, […]